FindTrial
Sign In

Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis

Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02457585
Enrollment
11
Registered
2015-05-29
Start date
2015-03-31
Completion date
2018-04-30
Last updated
2017-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takayasu's Arteritis

Brief summary

Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis. This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11

Detailed description

Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis. This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11 patients with active takayasu's arteritis

Interventions

DRUGremicade (anti tumor necrosis factor inhibitor)

single arm:remicade treatment group

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* active takayasu's arteritis

Exclusion criteria

* active Tuberculosis * Liver function abnormality * heart failure ( New York Heart Association III - IV) * patients were not consented

Design outcomes

Primary

MeasureTime frame
remission induction at 30 weeks30 weeks

Countries

South Korea

Contacts

Primary ContactSang Jin Lee, MD
dream1331@naver.com82-10-8623-2648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026